These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7256782)

  • 1. Allylamine cardiotoxicity: III. Protection by semicarbazide and in vivo derangements of monoamine oxidase.
    Boor PJ; Nelson TJ
    Toxicology; 1980; 18(2):87-102. PubMed ID: 7256782
    [No Abstract]   [Full Text] [Related]  

  • 2. Allylamine-induced vascular toxicity in vitro: prevention by semicarbazide-sensitive amine oxidase inhibitors.
    Ramos K; Grossman SL; Cox LR
    Toxicol Appl Pharmacol; 1988 Aug; 95(1):61-71. PubMed ID: 2842890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart.
    Toraason M; Luken ME; Breitenstein M; Krueger JA; Biagini RE
    Toxicology; 1989 May; 56(1):107-17. PubMed ID: 2728003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of benzylamine oxidase in the cytotoxicity of allylamine toward aortic smooth muscle cells.
    Hysmith RM; Boor PJ
    Toxicology; 1988 Oct; 51(2-3):133-45. PubMed ID: 3140421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allylamine cardiotoxicity--IV. Metabolism to acrolein by cardiovascular tissues.
    Nelson TJ; Boor PJ
    Biochem Pharmacol; 1982 Feb; 31(4):509-14. PubMed ID: 7066019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo effects of (E)-2-(3',4'-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues.
    Elliott J; Callingham BA; Barrand MA
    J Pharm Pharmacol; 1989 Jan; 41(1):37-41. PubMed ID: 2565962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allylamine cardiotoxicity: I. Sequence of pathologic events.
    Boor PJ; Moslen MT; Reynolds ES
    Toxicol Appl Pharmacol; 1979 Sep; 50(3):581-92. PubMed ID: 516068
    [No Abstract]   [Full Text] [Related]  

  • 8. The deamination of n-pentylamine by monoamine oxidase and a semicarbazide-sensitive amine oxidase of rat heart.
    Guffroy C; Fowler CJ; Strolin Benedetti M
    J Pharm Pharmacol; 1983 Jul; 35(7):416-20. PubMed ID: 6136581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Semicarbazide protection from in vivo oxidant injury of vascular tissue by allylamine.
    Awasthi S; Boor PJ
    Toxicol Lett; 1993 Feb; 66(2):157-63. PubMed ID: 8430435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allylamine cardiotoxicity: II. Histopathology and histochemistry.
    Boor PJ; Nelson TJ; Chieco P
    Am J Pathol; 1980 Sep; 100(3):739-64. PubMed ID: 6448005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase.
    Bey P; Fozard J; Lacoste JM; McDonald IA; Zreika M; Palfreyman MG
    J Med Chem; 1984 Jan; 27(1):9-10. PubMed ID: 6690689
    [No Abstract]   [Full Text] [Related]  

  • 12. Allylamine cardiotoxicity: metabolism and mechanism.
    Boor PJ
    Adv Exp Med Biol; 1983; 161():533-41. PubMed ID: 6346821
    [No Abstract]   [Full Text] [Related]  

  • 13. Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide.
    Visentin V; Bour S; Boucher J; Prévot D; Valet P; Ordener C; Parini A; Carpéné C
    Eur J Pharmacol; 2005 Oct; 522(1-3):139-46. PubMed ID: 16202994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and biochemical actions of the hemolytic agents acetylphenylhydrazine and phenylhydrazine on monoamine oxidase in the rat.
    Symes AL; Sourkes TL
    Biochem Pharmacol; 1974 Jul; 23(14):2045-56. PubMed ID: 4422032
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of 1-(indolyl-2-carbonyl)-2-alkyl-hydrazine derivatives on amine levels and monoamine oxidase activity in rat tissues.
    Vega P; Borrell S
    Biochem Pharmacol; 1972 Oct; 21(19):2571-5. PubMed ID: 4661618
    [No Abstract]   [Full Text] [Related]  

  • 16. Inhibition of semicarbazide-sensitive amine oxidase by monoamine oxidase B inhibitors from the oxazolidinone series.
    Dostert P; Guffroy C; Strolin Benedetti M; Boucher T
    J Pharm Pharmacol; 1984 Nov; 36(11):782-5. PubMed ID: 6150988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoamine oxidase and semicarbazide-sensitive amine oxidase in spontaneously hypertensive and in normotensive control rats.
    Guffroy C; Strolin Benedetti M
    Life Sci; 1984 Feb; 34(6):535-45. PubMed ID: 6694535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental vasculotoxicity associated with inhibition of semicarbazide-sensitive amine oxidase.
    Langford SD; Trent MB; Balakumaran A; Boor PJ
    Toxicol Appl Pharmacol; 1999 Mar; 155(3):237-44. PubMed ID: 10079209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substrate-selective and tissue-selective inhibition of monoamine oxidase.
    Fuller RW; Roush BW
    Arch Int Pharmacodyn Ther; 1972 Aug; 198(2):270-6. PubMed ID: 5054735
    [No Abstract]   [Full Text] [Related]  

  • 20. The enhanced daily excretion of urinary methylamine in rats treated with semicarbazide or hydralazine may be related to the inhibition of semicarbazide-sensitive amine oxidase activities.
    Lyles GA; McDougall SA
    J Pharm Pharmacol; 1989 Feb; 41(2):97-100. PubMed ID: 2568436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.